Bristol Goodwill and Intangible Assets vs Assets Non Current Analysis

BMY Stock  USD 53.25  0.70  1.33%   
Trend analysis of Bristol Myers Squibb balance sheet accounts such as Short Long Term Debt Total of 43.5 B, Other Current Liabilities of 12.1 B or Total Current Liabilities of 23.4 B provides information on Bristol Myers' total assets, liabilities, and equity, which is the actual value of Bristol-Myers Squibb to its prevalent stockholders. By breaking down trends over time using Bristol Myers balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

About Bristol Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bristol-Myers Squibb at a specified time, usually calculated after every quarter, six months, or one year. Bristol Myers Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bristol Myers and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bristol currently owns. An asset can also be divided into two categories, current and non-current.

Bristol Myers Balance Sheet Chart

Bristol Myers Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Bristol-Myers Squibb uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Bristol Myers' Good Will is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 99.9 B in 2024, whereas Total Stockholder Equity is likely to drop slightly above 15 B in 2024.

Total Assets

Total assets refers to the total amount of Bristol Myers assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bristol-Myers Squibb books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Bristol Myers balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bristol Myers Squibb are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol-Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
At this time, Bristol Myers' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 12.21 in 2024, whereas Discontinued Operations is likely to drop slightly above 6 B in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit36.4B36.0B34.3B36.0B
Total Revenue46.4B46.2B45.0B47.3B

Bristol Myers fundamental ratios Correlations

0.980.810.930.890.780.98-0.070.90.990.520.830.760.970.460.990.82-0.160.880.990.70.940.850.960.60.88
0.980.780.920.840.791.0-0.160.940.970.380.880.820.980.520.990.76-0.240.890.990.760.950.890.950.570.91
0.810.780.950.550.690.81-0.10.630.770.640.550.770.810.420.760.520.10.60.830.770.870.670.650.620.73
0.930.920.950.70.80.93-0.070.810.890.520.750.880.950.430.90.66-0.040.730.940.870.970.840.80.660.85
0.890.840.550.70.750.840.130.790.910.410.730.50.820.450.880.9-0.140.820.850.430.760.730.930.620.81
0.780.790.690.80.750.790.280.730.760.190.70.770.840.430.780.64-0.130.530.80.750.790.780.70.850.85
0.981.00.810.930.840.79-0.170.90.980.420.830.820.980.530.990.77-0.210.890.990.760.930.890.950.560.91
-0.07-0.16-0.1-0.070.130.28-0.17-0.12-0.07-0.11-0.07-0.11-0.03-0.61-0.120.170.35-0.45-0.11-0.06-0.05-0.16-0.130.44-0.14
0.90.940.630.810.790.730.9-0.120.870.210.980.780.90.470.920.66-0.320.830.910.690.910.850.870.570.84
0.990.970.770.890.910.760.98-0.070.870.530.80.710.950.460.990.84-0.190.890.980.650.910.830.980.570.86
0.520.380.640.520.410.190.42-0.110.210.530.120.160.380.170.450.490.120.440.480.180.450.180.450.210.35
0.830.880.550.750.730.70.83-0.070.980.80.120.760.840.40.850.6-0.370.740.840.670.870.80.80.580.78
0.760.820.770.880.50.770.82-0.110.780.710.160.760.880.370.760.48-0.290.580.80.970.860.870.620.530.8
0.970.980.810.950.820.840.98-0.030.90.950.380.840.880.410.970.78-0.190.810.980.830.950.90.90.630.89
0.460.520.420.430.450.430.53-0.610.470.460.170.40.370.410.50.21-0.330.690.490.320.410.540.510.290.65
0.990.990.760.90.880.780.99-0.120.920.990.450.850.760.970.50.8-0.220.90.990.690.930.860.970.580.88
0.820.760.520.660.90.640.770.170.660.840.490.60.480.780.210.8-0.070.720.780.450.690.650.860.520.75
-0.16-0.240.1-0.04-0.14-0.13-0.210.35-0.32-0.190.12-0.37-0.29-0.19-0.33-0.22-0.07-0.33-0.18-0.19-0.07-0.32-0.240.15-0.26
0.880.890.60.730.820.530.89-0.450.830.890.440.740.580.810.690.90.72-0.330.870.490.770.780.940.30.81
0.990.990.830.940.850.80.99-0.110.910.980.480.840.80.980.490.990.78-0.180.870.750.960.870.950.610.89
0.70.760.770.870.430.750.76-0.060.690.650.180.670.970.830.320.690.45-0.190.490.750.820.830.550.560.75
0.940.950.870.970.760.790.93-0.050.910.910.450.870.860.950.410.930.69-0.070.770.960.820.850.840.680.86
0.850.890.670.840.730.780.89-0.160.850.830.180.80.870.90.540.860.65-0.320.780.870.830.850.820.530.84
0.960.950.650.80.930.70.95-0.130.870.980.450.80.620.90.510.970.86-0.240.940.950.550.840.820.50.83
0.60.570.620.660.620.850.560.440.570.570.210.580.530.630.290.580.520.150.30.610.560.680.530.50.64
0.880.910.730.850.810.850.91-0.140.840.860.350.780.80.890.650.880.75-0.260.810.890.750.860.840.830.64
Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets129.9B118.5B109.3B96.8B95.2B99.9B
Short Long Term Debt Total47.5B51.7B45.6B40.7B41.5B43.5B
Other Current Liab7.9B10.2B10.1B13.1B11.5B12.1B
Total Current Liabilities18.3B19.1B21.9B21.9B22.3B23.4B
Total Stockholder Equity51.6B37.8B35.9B31.1B29.4B15.0B
Property Plant And Equipment Net6.3B6.7B7.0B7.5B8.0B5.2B
Net Debt35.2B37.1B31.6B31.6B30B31.5B
Retained Earnings34.5B21.3B23.8B25.5B28.8B22.0B
Cash12.3B14.5B14.0B9.1B11.5B12.0B
Non Current Assets Total100.6B88.3B76.1B69.5B63.4B66.6B
Non Currrent Assets Other6.6B2.1B1.7B1.0B1.9B2.0B
Cash And Short Term Investments12.3B14.5B14.0B9.1B12.3B12.9B
Net Receivables7.7B8.5B12.5B13.9B15.3B16.0B
Good Will22.5B20.5B20.5B21.1B21.2B22.2B
Common Stock Shares Outstanding1.6B1.7B2.3B2.2B2.1B1.6B
Liabilities And Stockholders Equity129.9B118.5B109.3B96.8B95.2B99.9B
Non Current Liabilities Total59.9B61.5B51.4B43.8B43.4B45.6B
Inventory4.3B2.1B2.1B2.3B2.7B1.9B
Other Current Assets2.0B1.4B1.3B1.6B1.5B1.8B
Other Stockholder Equity18.4B18.1B13.1B6.5B1.9B2.0B
Total Liab78.2B80.6B73.3B65.7B65.7B69.0B
Property Plant And Equipment Gross6.3B5.9B11.0B11.6B12.8B13.5B
Total Current Assets29.4B30.2B33.3B27.3B31.8B33.4B
Accumulated Other Comprehensive Income(1.5B)(1.8B)(1.3B)(1.3B)(1.5B)(1.6B)
Short Term Debt3.5B2.5B5.1B4.4B3.3B3.4B
Intangible Assets64.0B53.2B42.8B36.4B27.5B28.9B
Accounts Payable2.4B2.7B2.9B3.0B3.3B1.9B
Short Term Investments3.0B1.3B3.2B130M816M775.2M
Other Liab15.9B12.3B11.0B7.4B8.5B4.9B
Other Assets4.8B7.3B3.3B2.9B3.3B3.3B
Long Term Debt43.4B48.3B39.6B35.1B36.7B38.5B
Treasury Stock(19.6B)(25.4B)(26.2B)(31.3B)(28.1B)(26.7B)
Property Plant Equipment6.3B5.9B6.0B6.3B7.2B5.8B
Current Deferred Revenue4.5B3.6B3.7B1.3B4.2B4.4B
Net Tangible Assets(34.9B)(36.0B)(28.2B)(25.9B)(23.4B)(22.2B)
Noncontrolling Interest In Consolidated Entity96M100M60M57M65.6M75.7M
Retained Earnings Total Equity34.5B21.3B23.8B25.5B23.0B24.5B

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

  0.69MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Bristol Stock

  0.7MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.6MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.56KA Kineta Inc Report 29th of March 2024 PairCorr
  0.56VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bristol-Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
CEOs Directory
Screen CEOs from public companies around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.